Search Results - "THOMAS, Simu K"

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria by O’Connell, Thomas, Buessing, Marric, Johnson, Scott, Tu, Lufei, Thomas, Simu K., Tomazos, Ioannis

“…Background Paroxysmal nocturnal hemoglobinuria, characterized by intravascular hemolysis and venous thrombosis, can be managed with eculizumab, an inhibitor of…”
Get full text

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma by Maziarz, Richard T., Hao, Yanni, Guerin, Annie, Gauthier, Genevieve, Gauthier-Loiselle, Marjolaine, Thomas, Simu K., Eldjerou, Lamis

“…This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT)…”
Get full text

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review by Delea, Thomas E., Edelsberg, John, Sofrygin, Oleg, Thomas, Simu K., Baladi, Jean-Francois, Phatak, Pradyumna D., Coates, Thomas D.

“…BACKGROUND: Patients with thalassemia major require iron chelation therapy (ICT) to prevent complications from transfusional iron overload. Deferoxamine is…”
Get full text

Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia by DARKOW, Theodore, HENK, Henry J, THOMAS, Simu K, WEIWEI FENG, BAIADI, Jean-Francois, GOLDBERG, George A, HATFIELD, Alan, CORTES, Jorge

“…Identify treatment interruptions and non-adherence with imatinib; examine the clinical and patient characteristics related to treatment interruptions and…”
Get full text

Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany by Mayerhoff, Lukas, Lehne, Moritz, Hickstein, Lennart, Salimullah, Tayyab, Prieur, Sigurd, Thomas, Simu K, Zhang, Jie

“…Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension by Delea, Thomas E, Taneja, Charu, Moynahan, Aaron, Thomas, Simu K, Frech-Tamas, Feride, Oster, Gerry

“…The objective of this study was to compare cardiovascular and renal events in patients with hypertension receiving the angiotensin II-receptor blocker…”
Get full text

The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinson’s Disease: A Retrospective Claims-Based Analysis by Delea, Thomas E., Thomas, Simu K., Hagiwara, May

“…Background: Suboptimal adherence to long-term therapies is common and may potentially have adverse consequences on patient outcomes and healthcare costs…”
Get full text

Caregiver preference for rivastigmine patches versus capsules for the treatment of alzheimer disease by BLESA, Rafael, BALLARD, Clive, ORGOGOZO, Jean-Marc, LANE, Roger, THOMAS, Simu K

“…Alzheimer disease (AD) has a significant impact on caregivers. Administering and managing medications is one of their many daily tasks. More effective modes of…”
Get full text

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease by Winblad, Bengt, Kawata, Ariane K., Beusterien, Kathleen M., Thomas, Simu K., Wimo, Anders, Lane, Roger, Fillit, Howard, Blesa, Rafael

“…Background Family caregivers comprise a critical component in the care of Alzheimer's disease (AD) patients. Among their many tasks, caregivers are responsible…”
Get full text

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models by Nagy, Balázs, Brennan, Alan, Brandtmüller, Ágnes, Thomas, Simu K., Sullivan, Sean D., Akehurst, Ron

“…ObjectiveAssess long‐term cost‐effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models…”
Get full text

Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias by HILL, Jerrold, FILLIT, Howard, THOMAS, Simu K, CHANG, Sobin

“…The progressive decline in functional status for patients with Alzheimer's disease and other dementias (ADOD) is well documented. However, there is limited…”
Get full text

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare system perspective by DELEA, Thomas E, SOFRYGIN, Oleg, THOMAS, Simu K, BALADI, Jean-Francois, PHATAK, Pradyumna D, COATES, Thomas D

“…Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron concentrations and serum ferritin levels to a similar…”
Get full text

TREATMENT PERSISTENCY WITH RIVASTIGMINE AND DONEPEZIL IN A LARGE STATE MEDICAID PROGRAM by Singh, Gurkirpal, Thomas, Simu K, Arcona, Steve, Lingala, Vijayabharathi, Mithal, Alka

Get full text

Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease by Delea, Thomas E., Thomas, Simu K., Hagiwara, May, Mancione, L.

“…Observational studies suggest that single-tablet formulations are associated with improved adherence versus the same components taken as separate tablets. The…”
Get full text

Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase Inhibitors by Mincey, Betty A., Duh, Mei Sheng, Thomas, Simu K., Moyneur, Erick, Marynchencko, Maryna, Boyce, Simone Peart, Mallett, David, Perez, Edith A.

“…Aromatase inhibitors (AIs) are a novel hormonal therapy for patients with breast cancer. However, AIs can cause bone loss by blocking estrogen production. This…”
Get full text

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant by Maziarz, Richard T, Guérin, Annie, Gauthier, Geneviève, Heroux, Julie, Zhdanava, Maryia, Wu, Eric Q, Thomas, Simu K, Chen, Lei

“…To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute…”
Get full text

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States by Delea, Thomas E., Hagiwara, May, Thomas, Simu K., Baladi, Jean‐Francois, Phatak, Pradyumna D., Coates, Thomas D.

“…Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload. Data on the utilization and costs of care among U.S…”
Get full text

Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil by Hatoum, Hind T, Thomas, Simu K, Lin, Swu-Jane, Lane, Roger, Bullock, Roger

“…To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients. Models…”
Get more information

Drug persistency of two cholinesterase inhibitors : Rivastigmine versus donepezil in elderly patients with Alzheimer's disease by SUH, Dong-Churl, THOMAS, Simu K, VALIYEVA, Elmira, ARCONA, Stephen, VO, Lien

“…To compare persistency rates and persistency days in patients with Alzheimer's disease (AD) who initiated therapy with either rivastigmine or donepezil, and to…”
Get full text

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer by Delea, Thomas E, Karnon, Jon, Sofrygin, Oleg, Thomas, Simu K, Papo, Natalie L, Barghout, Victoria

“…Abstract Background In Breast International Group (BIG) 1–98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole…”
Get full text